Article
Oncology
Luai Al-Marzouki, Vivian S. Stavrakos, Sanjima Pal, Betty Giannias, France Bourdeau, Roni Rayes, Nicholas Bertos, Sara Najmeh, Jonathan D. Spicer, Jonathan Cools-Lartigue, Swneke D. Bailey, Lorenzo Ferri, Veena Sangwan
Summary: This study suggests that the contact between gastric adenocarcinoma cells and MA increases their ability to adhere to peritoneal cells. This finding is validated through ex vivo and in vivo experiments, and it is found that MIF and VEGF are elevated in MA samples from GC patients. Agents targeting MIF or VEGF may be used for the treatment or prevention of PM in GC patients.
Article
Multidisciplinary Sciences
Jiaojiao Pang, Feng Xu, Gianmarco Aondio, Yu Li, Alberto Fumagalli, Ming Lu, Giuseppe Valmadre, Jie Wei, Yuan Bian, Margherita Canesi, Giovanni Damiani, Yuan Zhang, Dexin Yu, Jun Chen, Xiang Ji, Wenhai Sui, Bailu Wang, Shuo Wu, Attila Kovacs, Miriam Revera, Hao Wang, Xu Jing, Ying Zhang, Yuguo Chen, Yihai Cao
Summary: In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO(2) ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Josephine Hendrikson, Ying Liu, Wai Har Ng, Jing Yi Lee, Abner Herbert Lim, Jui Wan Loh, Cedric C. Y. Ng, Whee Sze Ong, Joey Wee-Shan Tan, Qiu Xuan Tan, Gillian Ng, Nicholas B. Shannon, Weng Khong Lim, Tony K. H. Lim, Clarinda Chua, Jolene Si Min Wong, Grace Hwei Ching Tan, Jimmy Bok Yan So, Khay Guan Yeoh, Bin Tean Teh, Claramae Shulyn Chia, Khee Chee Soo, Oi Lian Kon, Iain Beehuat Tan, Jason Yongsheng Chan, Melissa Ching Ching Teo, Chin-Ann J. Ong
Summary: This study demonstrates the importance of the STAT3 signaling pathway in peritoneal carcinomatosis and identifies potential activating ligands. The study also validates the prognostic biomarker panel, including PAI-1, and highlights a therapeutic opportunity based on paracrine addiction.
CELL REPORTS MEDICINE
(2022)
Article
Genetics & Heredity
Ochuwa Adiketu Babah, Oyesola Oyewole Ojewunmi, Akinniyi Adediran Osuntoki, Melissa A. Simon, Bosede Bukola Afolabi
Summary: The study aimed to investigate the association between VEGF gene polymorphisms and endometriosis in Nigerian women. Results showed no significant difference in VEGF levels between cases and controls, and the distribution of VEGF gene polymorphisms was also not significantly different between endometriosis patients and controls.
Article
Oncology
Menglu Zhang, Jiaqi Liu, Gang Liu, Zeyu Xing, Ziqi Jia, Jiaxin Li, Wenyan Wang, Jie Wang, Ling Qin, Xin Wang, Xiang Wang
Summary: Breast cancer, the highest incidence of female malignancy, is heavily reliant on neo-vascularization for growth and metastasis, with Vascular Endothelial Growth Factor (VEGF) playing a crucial role. This review focuses on the prognostic value of VEGF in breast cancer, clinical experiences with anti-VEGF therapeutics, and biomarkers for predicting the effectiveness of anti-angiogenic treatment.
Article
Biochemistry & Molecular Biology
Qizhi Ma, Xia He, Benxia Zhang, Fuchun Guo, Xuejin Ou, Qiyu Yang, Pei Shu, Yue Chen, Kai Li, Ge Gao, Yajuan Zhu, Diyuan Qin, Jie Tang, Xiaoyu Li, Meng Jing, Jian Zhao, Zeming Mo, Ning Liu, Yao Zeng, Kexun Zhou, Mingyang Feng, Weiting Liao, Wanting Lei, Qiu Li, Dan Li, Yongsheng Wang
Summary: Pleural and peritoneal metastasis often occur with malignant pleural effusion (MPE) or malignant ascites (MA) in advanced solid tumor patients. This study reveals that the components of MPE/MA inhibit the anti-tumor cytotoxicity of conventional CAR-T cells by impairing their proliferation and cytokine production. The expression of PD-L1 on MPE/MA cells led to the design of a novel PD-L1-targeting chimeric switch receptor (PD-L1.BB CSR) that enhances the functions of CAR-T cells. The modified CAR-T cells with PD-L1.BB CSR showed superior fitness and efficacy in eradicating metastatic tumors in xenograft models.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Medicine, Research & Experimental
Furong Kou, Jifang Gong, Yan Li, Jian Li, Xiaotian Zhang, Jie Li, Lin Shen
Summary: This study evaluated the safety and efficacy of intraperitoneal bevacizumab for managing refractory malignant ascites and recommended further study using a dose of 7.5 mg/kg. Bevacizumab was well tolerated at doses from 2.5 to 7.5 mg/kg, and the maximum tolerated dose was not reached.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2021)
Article
Oncology
Golo Petzold, Sebastian C. B. Bremer, Felix C. Heuschert, Hannes Treiber, Volker Ellenrieder, Steffen Kunsch, Albrecht Neesse
Summary: Recurrent abdominal fluid collection, or ascites, is a common issue in patients with advanced malignancy, causing discomfort and other symptoms. Tunnelled peritoneal PleurX catheters have been shown to effectively reduce ascites-related symptoms and hospitalization rates, and are a safe and routine option for patients with recurrent malignant ascites.
Article
Oncology
Yuan Jiao, Xiaobo Peng, Yujie Wang, Zhibin Hao, Ling Chen, Meihong Wu, Yingyi Zhang, Jie Li, Wenlin Li, Xianbao Zhan
Summary: Malignant ascites (MA), a common symptom of advanced gastric cancer (GC) with peritoneal metastasis (PM), is associated with poor prognosis. This study investigated the effects of MA on cancer cell proliferation and the underlying mechanisms. The results demonstrated that MA treatment enhanced the proliferation of GC cells, and RNA sequencing revealed that asparagine synthetase (ASNS) was differentially expressed. Further analysis showed that MA upregulated ASNS expression, and downregulation of ASNS alleviated the stimulatory effect of MA on cancer cell proliferation. Additionally, the study revealed that MA activated the ATF4-ASNS axis to promote GC cell proliferation.
Article
Oncology
Francois-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, Capucine Baldini, Andrea Varga, Andrey A. Yurchenko, Audrey Rabeau, Stephane Champiat, Diane Letourneur, Delphine Bredel, Sandrine Susini, Yuna Blum, Aurelien Parpaleix, Cedric Parlavecchio, Lambros Tselikas, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Mathieu Rouanne, Saloomeh Rafie, Alae Abbassi, Ines Kasraoui, Marie Breckler, Siham Farhane, Samy Ammari, Salim Laghouati, Anas Gazzah, Ludovic Lacroix, Benjamin Besse, Nathalie Droin, Marc Deloger, Sophie Cotteret, Julien Adam, Laurence Zitvogel, Sergey I. Nikolaev, Nathalie Chaput, Christophe Massard, Jean-Charles Soria, Carlos Gomez-Roca, Gerard Zalcman, David Planchard, Aurelien Marabelle
Summary: Recent research has shown that cancer immunotherapy combinations can improve the overall survival of advanced mesotheliomas, especially for patients who respond to the treatments. This study aimed to understand the biological factors that contribute to the primary resistance of mesotheliomas to immunotherapy and antiangiogenics. The combination of pembrolizumab and nintedanib was tested in thirty patients with advanced malignant pleural mesothelioma, and it was observed that refractory patients recruited cytotoxic T cells in their tumors but had high levels of somatic copy-number alterations and proinflammatory cytokines.
Article
Medicine, General & Internal
Andreas Stahl, Emine A. Sukgen, Wei-Chi Wu, Domenico Lepore, Hidehiko Nakanishi, Jan Mazela, Darius M. Moshfeghi, Robert Vitti, Aditya Athanikar, Karen Chu, Pablo Iveli, Fei Zhao, Thomas Schmelter, Sergio Leal, Evra Kofuncu, Noriyuki Azuma
Summary: In infants with ROP, intravitreal aflibercept did not meet the criteria for noninferiority compared to laser photocoagulation in terms of treatment success at week 24. Rescue treatment was less required in the intravitreal aflibercept group, but the serious adverse event rates were higher in the laser photocoagulation group. Further data would be needed for more definitive conclusions on the comparative effects of these treatments.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Review
Medicine, General & Internal
Nada O. Taher, Abdullah A. Ghaddaf, Sarah A. Al-Ghamdi, Jumanah J. Homsi, Bandar J. Al-Harbi, Lugean K. Alomari, Hashem S. Almarzouki
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of anti-VEGF monotherapy for retinopathy of prematurity (ROP). The results showed that anti-VEGF monotherapy had fewer adverse events compared to laser therapy, with no significant differences in other outcomes.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Cuiju Wang, Yalei Lv, Ziyue Sha, Jingjing Zhang, Jianhua Wu, Yixin Qi, Zhanjun Guo
Summary: The study showed that Dicer inhibited proliferation, migration, and invasion of HCC cells by suppressing VEGF-A expression, with VEGF-A165 counteracting this inhibition. Combination of bevacizumab and Dicer synergistically reduced tumor microvessel density.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Multidisciplinary Sciences
Yi Ding, Leticia Oliveira-Ferrer, Eike Vettorazzi, Karen Legler, Karin Milde-Langosch, Linn Woelber, Anna Jaeger, Katharina Prieske, Volkmar Mueller, Barbara Schmalfeldt, Sascha Kuerti
Summary: This study investigated the potential of vascular endothelial growth factor C (VEGF-C) in serum as a predictive biomarker for response to antiangiogenic therapy in ovarian cancer patients. The results showed that patients with higher levels of VEGF-C in serum had significantly increased chances of response to bevacizumab treatment. Therefore, VEGF-C serum level may serve as a useful biomarker for evaluating treatment response to bevacizumab.
Article
Medicine, General & Internal
Yan Gu, Wanung Yang, Min Zhang, Xiaolu Yang, Xinhua Fu
Summary: The study showed that in the management of malignant pleural effusion caused by lung adenocarcinoma, Bevacizumab and OK-432 are similarly effective, but the former has fewer adverse reactions, can effectively reduce serum VEGF levels, shorten hospital stays, and reduce hospital costs.
ACTA MEDICA MEDITERRANEA
(2021)